Thymosin Beta 4 5mg

Thymosin beta-4 and cellular movement

Thymosin Beta 4 5mg is the full-length 43-amino-acid peptide commonly abbreviated Tβ4 or TB4. A central part of its biology is binding monomeric actin, which connects it with the organisation of the cytoskeleton and the processes cells use to move.

Actin regulation as a research foundation

Cell experiments have shown coordinated changes in actin and related structural proteins when thymosin beta-4 levels are altered. This provides mechanistic context for wider interest in cell migration and tissue repair, where movement and structural organisation are important features.

Human ophthalmic investigations

The eye-drop formulation RGN-259 has been investigated in human dry-eye studies. A small severe-dry-eye trial reported improvements in selected signs and symptoms. A separate 72-participant phase 2 study found improvements in several secondary measures, although its prespecified primary endpoints were not significantly different from placebo.

These clinical observations add a formulation-specific human dimension to the cellular research. They do not establish equivalent effects from a research vial or for unrelated injury-recovery outcomes.

Full-length thymosin beta-4 should also be distinguished from the acetylated seven-residue fragment identified as TB-500 in analytical studies. Keeping the molecular identity clear makes comparisons between papers more useful.

Also known as / branded as

• Thymosin beta-4
• Thymosin β4
• Tβ4
• Tβ-4
• TB4